Washington Research Foundation

Washington Research Foundation operates as a geographically concentrated private funder with an unusually specific mandate: all grantees must be nonprofit research institutions in Washington state, and for technology commercialization work, intellectual property must be institutionally owned. This constraint dramatically narrows the eligible universe — if your organization doesn't meet this test, no proposal will succeed regardless of scientific merit.

WRF's giving philosophy centers on translational research: moving discoveries from bench to bedside or market. The foundation explicitly frames its mission around transforming research into "products and services that will improve health and advance technology for public benefit." Every proposal must articulate a commercialization pathway, not merely scientific contribution. The clearest language to use is around public benefit through novel technologies, products, services, or discoveries.

The foundation runs a phased funding model for technology commercialization. Phase 1 grants cover proof-of-concept work, Phase 2 funds continued development and validation, and Phase 3 backs commercialization-readiness. Entry into this pipeline almost always starts at Phase 1 — the grantee database shows repeating patterns: "CRAVEN KRAS PHASE 1," "UW FOLCH: PHASE I/II/III," "UW ROY: PHASE I." If your technology is early-stage, position the first application as Phase 1 without attempting to skip the sequence.

The University of Washington commands roughly 55% of all WRF grant dollars (546 awards totaling $36M in the database), but WRF actively funds other WA institutions: Washington State University ($11.6M), Fred Hutchinson Cancer Center (~$6.8M), Seattle Children's Research Institute ($4.6M), Institute for Systems Biology ($1.5M), Western Washington University ($546K), and Benaroya Research Institute ($543K). A 2025 first-ever grant to Seattle University signals the foundation is open to adding new institutional relationships when scientific fit is compelling.

For first-time applicants, the entry point is a pre-proposal via WRF's online portal for technology commercialization grants, or direct contact at grants@wrfseattle.org. For postdoctoral fellowships, the annual window opens May 1 and closes in late June — attend the spring information sessions (Zoom and in-person) WRF holds before the deadline. Relationship-building with program staff is encouraged and strategically valuable at a foundation that has maintained decades of repeated engagement with its core institutional partners.

WRF's financial profile has expanded substantially over the past decade. Total assets grew from $167M in 2015 to $344M by 2023, driven by technology licensing revenues, contributions, and investment returns. Net investment income alone runs approximately $20.6M annually (2022-2023), comfortably exceeding total annual grants paid. Annual giving has risen steadily: $8.5M in 2018, $9.0M in 2019, $14.0M in 2020, peaking at $18.9M in 2021, then settling to $16.5M in 2022-2023. Total grants paid from operational funds ran $9.9M in 2022 and $12.5M in 2021.

Across 163 tracked technology commercialization and related grants, the range spans from $200 (small honorariums) to $2,000,000 (large commercialization awards), with a median of $22,500 and an average of $63,074. These numbers compress due to the inclusion of small ecosystem and student awards. The practical range by program tier looks quite different:

• Phase 1 technology grants: $30,000–$100,000 (proof of concept and feasibility)
• Phase 2 technology grants: $100,000–$500,000 (development and validation)
• Phase 3 technology grants: $500,000–$2,000,000 (pre-commercialization readiness)
• WRF Postdoctoral Fellowships: 3-year awards covering salary, benefits, and research expenses (approximately $65,000/year all-in, based on fellowship payout data)
• BioInnovation Grants: One-time large investments — the November 2025 award of $5.2M to Fred Hutch and Seattle Children's Research Institute is the most visible recent example
• Undergraduate research fellowships: $8,000 per recipient per year
• Equipment grants: $150,000–$200,000 (mass spectrometers, flow cytometers, multiphoton microscopes)

Geographically, 99.8% of grants flow to Washington state institutions (825 of 827 grants). The University of Washington alone accounts for 546 grants and $36M in documented awards — dwarfing all other recipients. Washington State University follows at $11.6M across 64 grants. The foundation has distributed more than $186M total since its founding in 1993, making it one of the most significant life sciences research funders operating in the Pacific Northwest.

The following table compares Washington Research Foundation to similar health and biomedical research foundations by assets, annual giving, focus, and application accessibility:

WRF is the largest funder in this peer group by assets and the most geographically concentrated, serving exclusively Washington state institutions. Unlike Wellcome Leap and Glenn Foundation — which fund by thematic program or explicit invitation — WRF maintains a structured open pre-proposal process for technology commercialization grants, making it comparatively accessible for qualifying WA institutions. WRF's dual emphasis on health/biomedical sciences and enabling technologies (engineering, computer science, environmental tech) differentiates it from narrowly defined cancer-only or aging-only funders like Walther and Glenn. The foundation's $5.2M BioInnovation award in 2025 demonstrates capacity for transformative single-grant investments that most peers in this asset range rarely attempt.

On December 17, 2025, WRF announced its 2026 cohort of 12 WRF Postdoctoral Fellows — the program's largest annual cohort since launching in 2018, now totaling 102 fellowships awarded across 90 labs at nine Washington institutions. The 2026 fellows will conduct research at UW, WSU, and the Institute for Systems Biology, pursuing projects in immunology, microbiome science, protein engineering, clean energy technologies, AI for urban sustainability, genomics, and cancer therapeutics. Applications for the 2027 cohort are expected to open in May 2026.

In November 2025, WRF awarded a $5.2 million BioInnovation Grant to Fred Hutchinson Cancer Center and Seattle Children's Research Institute to develop a clinical trials program for first-in-human studies. The grant funds an engineered TCR T-cell therapy for adult acute myeloid leukemia and a CAR T-cell therapy for pediatric AML, with $4M allocated to direct trial support (with institutional matching) and $1.2M for infrastructure. Director of Grant Programs Meher Antia stated the funding is designed to "strengthen the pipeline of early-stage research that actually reaches patients."

Leadership context: Thomas Daniel has served as President and CEO since October 2022, following a period when Susan Coliton served as Director/Interim CEO. Morgan Hellar is CFO/Treasurer/Secretary. Meher Antia leads grant programs; Clarisse Benson manages student and postdoctoral programs. The 2025 first-ever grant to Seattle University signals an intentional push to expand WRF's institutional footprint beyond its core UW/WSU/Fred Hutch relationships.

Confirm eligibility before everything else. WRF funds nonprofit research institutions in Washington state only — no exceptions, no waivers. This single criterion disqualifies the vast majority of U.S. researchers. For technology commercialization grants, also verify that intellectual property is owned at the institutional level, not by an individual PI or a commercial partner.

Choose the right program track. WRF runs four distinct funding streams: Technology Commercialization Grants (phased, Phase 1 through Phase 3), BioInnovation Grants (large one-time opportunities for major ecosystem initiatives), WRF Postdoctoral Fellowships (individual 3-year awards), and Student Programs (undergrad fellowships, currently closed cyclically). Each has different contacts, timelines, and application formats — do not conflate them.

Phase your ask correctly. New applicants to the Technology Commercialization track almost always enter at Phase 1 ($30K–$100K range). WRF's grantee database shows consistent Phase 1 → Phase 2 → Phase 3 progressions across multiple labs and institutions. Requesting Phase 2 funding without a Phase 1 track record at WRF is a difficult ask.

Lead with translational impact in every proposal. WRF's Director of Grant Programs Meher Antia has stated the foundation looks for research demonstrating "potential for future commercialization" alongside patient benefit. Map explicitly from scientific discovery to a specific product, service, or clinical application — and name the Washington state ecosystem connection. Generic science statements without a commercialization arc undercut proposals.

For postdoctoral fellowship applicants: The application window opens May 1 and closes in late June (exact 2026 deadline to be confirmed). You must have two years or fewer of postdoctoral experience when applications open. Propose a project that is intellectually independent from your mentor's existing program — WRF explicitly rewards applicant-driven creativity. Secure a mentor letter detailing specific lab support. Non-U.S. citizens must confirm work authorization with their host institution before applying.

Contact WRF staff early. Reach grants@wrfseattle.org (technology grants) or postdoc@wrfseattle.org (fellowships) well before submission. WRF holds spring information sessions (Zoom and in-person) ahead of fellowship deadlines — attendance signals genuine interest. Program staff advise on fit and have historically been accessible to prospective applicants at qualifying institutions.